This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wednesday's Health Winners & Losers

Shares of drug developer Progen Industries (PGLA) jumped more than 160% after the company announced positive results on an experimental cancer drug.

In clinical trials, patients who had cancerous tumors removed from their livers went 76% longer before tumor recurrence when given the drug, dubbed PI-88, compared with patients not on the treatment. Shares were up $4.75 to $7.70.

Shares of cancer drug developer Celgene (CELG) sank 2.7% to $55.99 after the company said that Barr Pharmaceuticals (BRL) is looking to market thalidomide, a generic version of Celgene's blood cancer drug Thalomid.

Barr intends to market its version as a treatment for a skin condition associated with leprosy, the first indication Celgene's branded version of the drug received. Thalomid was more recently approved to treat the blood cancer multiple myeloma, a condition with a much larger market than that of leprosy in the U.S.

Vertex Pharmaceuticals (VRTX) fell 1.5% to $38.80 after the company released results from an interim safety analysis of its hepatitis C drug telaprevir.

While 9% of patients receiving the drug in clinical trials discontinued treatment due to side effects, 65 out of 74 patients had undetectable levels of the virus after treatment, Vertex says. The company received a $15 million milestone payment from its partner, Johnson & Johnson (JNJ) unit Janssen Pharmaceutica based on the trial results.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,063.99 +10.28 0.06%
S&P 500 2,092.56 +3.79 0.18%
NASDAQ 4,808.4770 +1.6180 0.03%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs